Arthur Machlenkin

791 total citations
20 papers, 624 citations indexed

About

Arthur Machlenkin is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Arthur Machlenkin has authored 20 papers receiving a total of 624 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Immunology, 9 papers in Oncology and 5 papers in Molecular Biology. Recurrent topics in Arthur Machlenkin's work include Immunotherapy and Immune Responses (17 papers), Immune Cell Function and Interaction (13 papers) and T-cell and B-cell Immunology (9 papers). Arthur Machlenkin is often cited by papers focused on Immunotherapy and Immune Responses (17 papers), Immune Cell Function and Interaction (13 papers) and T-cell and B-cell Immunology (9 papers). Arthur Machlenkin collaborates with scholars based in Israel, United States and France. Arthur Machlenkin's co-authors include Lea Eisenbach, Ofir Goldberger, Ilan Volovitz, Esther Tzehoval, Ezra Vadai, Uri Liberman, Carmela Rotem, A. Hochman, Gania Kessler‐Icekson and Ruth Koren and has published in prestigious journals such as The Journal of Immunology, PLoS ONE and Cancer Research.

In The Last Decade

Arthur Machlenkin

20 papers receiving 608 citations

Peers

Arthur Machlenkin
Takaaki Oba Japan
Janina Dörr Germany
C Blattner Germany
Sarah McCuaig Canada
Agnieszka Graczyk‐Jarzynka Poland
Denise L. Cecil United States
You-Soo Park South Korea
Ya-Fang Chang United States
Sana Hibino Japan
Takaaki Oba Japan
Arthur Machlenkin
Citations per year, relative to Arthur Machlenkin Arthur Machlenkin (= 1×) peers Takaaki Oba

Countries citing papers authored by Arthur Machlenkin

Since Specialization
Citations

This map shows the geographic impact of Arthur Machlenkin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arthur Machlenkin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arthur Machlenkin more than expected).

Fields of papers citing papers by Arthur Machlenkin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Arthur Machlenkin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arthur Machlenkin. The network helps show where Arthur Machlenkin may publish in the future.

Co-authorship network of co-authors of Arthur Machlenkin

This figure shows the co-authorship network connecting the top 25 collaborators of Arthur Machlenkin. A scholar is included among the top collaborators of Arthur Machlenkin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Arthur Machlenkin. Arthur Machlenkin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Pan, Xiaoyu, Eran Ophir, Zoya Alteber, et al.. (2019). Mouse PVRIG Has CD8+ T Cell–Specific Coinhibitory Functions and Dampens Antitumor Immunity. Cancer Immunology Research. 7(2). 244–256. 45 indexed citations
2.
Eisenberg, Galit, Emma Hajaj, Sharon Merims, et al.. (2018). Soluble SLAMF6 Receptor Induces Strong CD8+ T-cell Effector Function and Improves Anti-Melanoma Activity In Vivo. Cancer Immunology Research. 6(2). 127–138. 19 indexed citations
3.
Eisenberg, Galit, Sharon Merims, Shoshana Frankenburg, et al.. (2015). Human T Cell Crosstalk Is Induced by Tumor Membrane Transfer. PLoS ONE. 10(2). e0118244–e0118244. 11 indexed citations
4.
Speck, Tobias, Tillmann Michels, Antonio Sorrentino, et al.. (2015). A high‐throughput RNA i screen for detection of immune‐checkpoint molecules that mediate tumor resistance to cytotoxic T lymphocytes. EMBO Molecular Medicine. 7(4). 450–463. 29 indexed citations
5.
Eisenberg, Galit, Arthur Machlenkin, Alon Margalit, et al.. (2015). Messenger RNA encoding constitutively active Toll-like receptor 4 enhances effector functions of human T cells. Clinical & Experimental Immunology. 182(2). 220–229. 15 indexed citations
6.
Eisenberg, Galit, Shoshana Frankenburg, Sharon Merims, et al.. (2013). Imprinting of Lymphocytes with Melanoma Antigens Acquired by Trogocytosis Facilitates Identification of Tumor-Reactive T Cells. The Journal of Immunology. 190(11). 5856–5865. 15 indexed citations
7.
Lotem, Michal, Luna Kadouri, Sharon Merims, et al.. (2011). HLA‐B35 correlates with a favorable outcome following adjuvant administration of an HLA‐matched allogeneic melanoma vaccine. Tissue Antigens. 78(3). 203–207. 2 indexed citations
8.
Volovitz, Ilan, Arthur Machlenkin, Ofir Goldberger, et al.. (2011). Split Immunity: Immune Inhibition of Rat Gliomas by Subcutaneous Exposure to Unmodified Live Tumor Cells. The Journal of Immunology. 187(10). 5452–5462. 16 indexed citations
9.
Eisenberg, Galit, Yael Sagi, Shoshana Frankenburg, et al.. (2011). Trogocytosis Is a Gateway to Characterize Functional Diversity in Melanoma-Specific CD8+ T Cell Clones. The Journal of Immunology. 188(2). 632–640. 24 indexed citations
10.
Eisenberg, Galit, Arthur Machlenkin, Shoshana Frankenburg, et al.. (2010). Transcutaneous immunization with hydrophilic recombinant gp100 protein induces antigen-specific cellular immune response. Cellular Immunology. 266(1). 98–103. 11 indexed citations
11.
Lotem, Michal, Arthur Machlenkin, Tamar Hamburger, et al.. (2009). Autologous Melanoma Vaccine Induces Antitumor and Self-Reactive Immune Responses That Affect Patient Survival and Depend on MHC Class II Expression on Vaccine Cells. Clinical Cancer Research. 15(15). 4968–4977. 17 indexed citations
12.
Goldberger, Ofir, Ilan Volovitz, Arthur Machlenkin, et al.. (2008). Exuberated Numbers of Tumor-Specific T Cells Result in Tumor Escape. Cancer Research. 68(9). 3450–3457. 28 indexed citations
13.
Machlenkin, Arthur, Shoshana Frankenburg, Galit Eisenberg, et al.. (2008). Capture of Tumor Cell Membranes by Trogocytosis Facilitates Detection and Isolation of Tumor-Specific Functional CTLs. Cancer Research. 68(6). 2006–2013. 35 indexed citations
14.
Tirosh, Boaz, Lior Carmon, Aviv Paz, et al.. (2007). ‘1-8 interferon inducible gene family’: putative colon carcinoma-associated antigens. British Journal of Cancer. 97(12). 1655–1663. 9 indexed citations
15.
Machlenkin, Arthur, Ronit Rosenfeld, Ilan Volovitz, et al.. (2006). Preventive and therapeutic vaccination with PAP-3, a novel human prostate cancer peptide, inhibits carcinoma development in HLA transgenic mice. Cancer Immunology Immunotherapy. 56(2). 217–226. 16 indexed citations
16.
Machlenkin, Arthur, Adrian Paz, Ofir Goldberger, et al.. (2005). Human CTL Epitopes Prostatic Acid Phosphatase-3 and Six-Transmembrane Epithelial Antigen of Prostate-3 as Candidates for Prostate Cancer Immunotherapy. Cancer Research. 65(14). 6435–6442. 64 indexed citations
17.
Machlenkin, Arthur, Ofir Goldberger, Boaz Tirosh, et al.. (2005). Combined Dendritic Cell Cryotherapy of Tumor Induces Systemic Antimetastatic Immunity. Clinical Cancer Research. 11(13). 4955–4961. 89 indexed citations
18.
Lee, Sung‐Hyung, Erez Bar‐Haim, Arthur Machlenkin, et al.. (2004). In vivo rejection of tumor cells dependent on CD8 cells that kill independently of perforin and FasL. Cancer Gene Therapy. 11(3). 237–248. 19 indexed citations
19.
Bar‐Haim, Erez, Aviv Paz, Arthur Machlenkin, et al.. (2004). MAGE-A8 overexpression in transitional cell carcinoma of the bladder: identification of two tumour-associated antigen peptides. British Journal of Cancer. 91(2). 398–407. 19 indexed citations
20.
Machlenkin, Arthur, Carmela Rotem, A. Hochman, et al.. (1999). 1,25-Dihydroxyvitamin D3 enhances the susceptibility of breast cancer cells to doxorubicin-induced oxidative damage.. PubMed. 59(4). 862–7. 141 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Takaaki Oba Breakdown of academic impact, for papers by Janina Dörr Breakdown of academic impact, for papers by C Blattner Breakdown of academic impact, for papers by Sarah McCuaig Breakdown of academic impact, for papers by Agnieszka Graczyk‐Jarzynka Breakdown of academic impact, for papers by Denise L. Cecil Breakdown of academic impact, for papers by You-Soo Park Breakdown of academic impact, for papers by Ya-Fang Chang Breakdown of academic impact, for papers by Sana Hibino
Rankless by CCL
2026